Does a post-merger life sciences company need a fractional CRO in 2027?

Direct Answer
Post-merger life sciences companies in 2027 face a specific challenge: two (or more) sales teams, two CRM instances, two pricing models, and two customer bases that must become one revenue machine. A fractional CRO provides the integration playbook and execution oversight without a permanent executive hire. You get someone who has done this before — likely in multiple life sciences verticals — and who can diagnose the revenue gaps, align the teams, and build the unified forecast in weeks, not quarters.
The cost range is wide because it depends on how many days per week you need, how much travel to sites is required, and whether you offer equity or performance bonuses. A light-touch advisory engagement (two days per month, remote) runs $8,000–$12,000/month. A hands-on interim CRO (three to four days per week, on-site at labs or manufacturing sites) runs $18,000–$25,000/month plus equity. Full-time CRO total compensation in life sciences (base + bonus + equity) lands at $400,000–$700,000 annually, so fractional is substantially cheaper for a 6–12 month integration phase.
Why Post-Merger Life Sciences Is Special in 2027
Life sciences companies — biotech, pharma, diagnostics, medical devices, and lab services — operate under regulatory constraints that shape every revenue motion. After a merger, you are not just combining sales teams; you are combining compliance protocols, approval processes, and customer qualification rules. A fractional CRO who has worked in life sciences understands how FDA regulations, HIPAA, and EU MDR affect deal timelines, contract language, and revenue recognition. They will not try to apply a generic SaaS sales playbook to a regulated environment.
In 2027, the life sciences M&A market is active but selective. Buyers are looking for platform companies with clear commercial alignment. If your merger was driven by pipeline or technology fit rather than commercial fit, you need someone who can build the commercial bridge between the two entities. A fractional CRO can design a unified territory plan, align compensation to the new combined goals, and create a single forecast that the board can trust.
What a Fractional CRO Actually Does in a Merger
A fractional CRO is not a coach or a consultant who gives advice and leaves. They are an executive who operates — they run the weekly revenue meeting, manage the sales ops team, review pipeline with each rep, and hold the sales leaders accountable. In a post-merger context, their specific deliverables include:
- CRM unification: Deciding which instance survives, migrating data, and cleaning duplicates. They will work with RevOps to get this done in 30–60 days.
- Compensation redesign: Creating a single comp plan that rewards both legacy teams fairly and drives the new combined behavior. This is politically charged and requires someone without internal baggage.
- Territory and quota alignment: Splitting the combined customer base into logical territories, setting quotas that are ambitious but achievable, and handling the inevitable disputes.
- Pipeline integration: Combining two pipelines into one forecast, applying consistent stage definitions, and identifying which deals are real and which are wishful thinking.
- Cultural integration: Running joint sales meetings, creating shared rituals, and modeling the behavior that says "we are one team now."
When a Fractional CRO Is the Wrong Answer
Fractional CROs are not a panacea. If your post-merger company has no revenue leadership at all — no VP of Sales, no sales ops, no one running the commercial function — a fractional CRO working two days a week will be insufficient. You need a full-time executive to rebuild the function from scratch.
If the merger is strategically flawed — for example, the two companies sell to completely different buyer personas with no overlap — no amount of commercial integration will create the revenue alignment the board expects. A fractional CRO can tell you this honestly in the first month, but you may not like the answer.
If your budget is under $5,000 per month for revenue leadership, you cannot afford a qualified fractional CRO. Look for a part-time VP of Sales or a senior sales consultant instead, but understand you will get less experience and less accountability.
How to Evaluate a Fractional CRO for Life Sciences
When interviewing fractional CROs for a post-merger life sciences company, ask these specific questions:
- "How many post-merger integrations have you led in life sciences?" Listen for number and context (biotech vs med device vs diagnostics).
- "What CRM did you unify and how long did it take?" They should have a concrete answer about data migration, field mapping, and user adoption.
- "How did you handle compensation disputes between legacy teams?" Look for examples of fairness and transparency, not just "I made a decision."
- "How do you handle FDA-regulated sales processes?" They should know that you cannot cold-call a lab director the same way you cold-call a SaaS buyer.
- "What tools do you use for forecasting and pipeline management?" They should name Salesforce, HubSpot, Clari, Gong, or Outreach and explain how they use them — not just list them.
The Mermaid Diagrams
Decision Flowchart for Post-Merger Revenue Leadership
Revenue Integration Timeline
FAQ
What is the difference between a fractional CRO and a sales consultant? A fractional CRO is an operating executive who runs the revenue function, attends your weekly leadership meetings, manages the sales team, and is accountable for results. A sales consultant gives advice, runs workshops, and delivers recommendations but does not manage people or own the forecast. For a post-merger integration, you need the operator, not the advisor.
Can a fractional CRO work remotely for a life sciences company? Yes, but with caveats. Life sciences often requires on-site visits to labs, manufacturing facilities, or key customer sites. If your fractional CRO is remote, they should plan to travel to your sites at least one week per month during the first three months. After that, remote with periodic visits works well.
How long does a fractional CRO typically stay post-merger? Most engagements run 6 to 18 months. The first 3 months are heavy on integration work (CRM, comp, territories). Months 4–12 focus on execution and building the new team's capability. By month 12–18, you should either hire a full-time CRO or have your VP of Sales ready to take over.
Will a fractional CRO replace my existing VP of Sales? Not necessarily. A fractional CRO typically works above the VP of Sales, providing strategic direction and integration expertise while the VP runs day-to-day sales execution. If the VP of Sales lacks integration experience, the fractional CRO can mentor them. If the VP of Sales is not performing, the fractional CRO can help you make that decision.
Do fractional CROs take equity? Some do, some do not. For a 6–12 month engagement, cash-only is common. For longer engagements or if the company is pre-revenue, equity is often part of the package. Expect to offer 0.5% to 2.0% equity for a fractional CRO who is deeply involved, vesting over the engagement period.
How do I know if a fractional CRO is actually good? Check their references from other life sciences companies, specifically asking about post-merger integration. Ask to see a sample integration plan or 30-60-90 day roadmap. Look for candidates who are members of Pavilion or RevOps Co-op, as these communities attract experienced revenue leaders. A good fractional CRO will also be willing to do a paid half-day diagnostic before you commit.
Sources
- Pavilion — community for revenue leaders
- RevOps Co-op — operations community
- Harvard Business Review — M&A integration articles
- First Round Review — leadership and scaling
- SaaStr — SaaS and revenue leadership
- LinkedIn — fractional CRO discussions and groups
- Salesforce — CRM best practices for mergers
People also search for: fractional cro · hire a fractional cro · fractional cro near me · fractional cro cost